Skip to main content
. 2023 Feb 2;18(2):e0281166. doi: 10.1371/journal.pone.0281166

Fig 2. Prognostic factors and primary treatment associated with patients’ overall survival.

Fig 2

Cumulative overall (%) survival time in months after 1-, 2 -and 5-year follow-up for (A) Age, (B) MGMT promoter methylation status, (C) IDH mutation status, (D) tumour location, (E) tumour multifocality, (F) extent of surgical resection and (G) treatment administered after primary tumour diagnosis. NOS = not otherwise specified.